北京若生智能科技有限公司
Drug Database
DE

delapril + indapamide (delapril/indapamide / Delapride)

✓ Approved

Chiesi Farmaceutici S.p.A. · ACE · 小分子

什么是 delapril + indapamide？

delapril + indapamide 是一种小分子，由Chiesi Farmaceutici S.p.A.研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名delapril/indapamide, Delapride
公司Chiesi Farmaceutici S.p.A.
药物类别小分子
分子靶点ACE, SLC12A3
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Chiesi Farmaceutici S.p.A.

作用机制

分子靶点

delapril + indapamide 作用于 2 个分子靶点：

ACEangiotensin I converting enzyme (DCP1, ACE1)
SLC12A3solute carrier family 12 member 3 (NCCT, NCC)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

delapril + indapamide 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedInternational journal of general medicine2026-09-06

Thiazide Diuretics Are Associated with a Higher Triglyceride-Glucose Index Than Calcium Channel Blockers in Hypertensive Patients.

Erarslan Sertas S, Acet Aycan A, Karagoz Osman Nurullah ON, Erkan Bugrahan B et al.

Hypertension is frequently accompanied by metabolic abnormalities that increase cardiovascular risk. The triglyceride-glucose (TyG) index is a practical surrogate marker of insulin resistance. This study aimed to compare TyG index values and related metabolic parameters between patients receiving RAAS blockers plus thiazide/thiazide-like diuretics and those receiving RAAS blockers plus calcium channel blockers (CCBs) as antihypertensive regimens. In this retrospective observational study, 157 of 189 screened patients met eligibility criteria and were included (RAAS blocker plus thiazide/thiazide-like diuretic, n=95; RAAS blocker plus CCB, n=62). Multivariable linear regression models and inverse probability of treatment weighting (IPTW) analyses were performed to assess the independence of findings from clinical confounders. The TyG index was significantly higher in the diuretic group than in the CCB group [9.21 (9.01-9.73) vs 8.95 (8.66-9.40); p<0.001], as were triglyceride [186.00 vs 142.35 mg/dL; p<0.001] and uric acid levels [5.70 vs 5.00 mg/dL; p=0.004]. Blood pressure control rates were similar. The treatment group effect remained significant across all adjusted models, including IPTW-weighted regression (β=0.385, p=0.0003). A significant treatment group × diabetes mellitus interaction was observed (p=0.042), suggesting a stronger association in diabetic patients. A dose-stratified analysis within the diuretic group showed a significant dose-response relationship: higher hydrochlorothiazide (25 vs 12.5 mg/day) and indapamide (2.5 vs 1.25 mg/day) doses were both associated with significantly higher TyG index, fasting glucose, and uric acid levels. In an exploratory diuretic subgroup analysis, urea and BUN levels were higher with hydrochlorothiazide than indapamide; however, this analysis was underpowered (indapamide n=24) and should be interpreted with caution. RAAS blocker plus thiazide/thiazide-like diuretic regimens were associated with a significantly higher TyG index and a less favorable metabolic profile than RAAS blocker plus CCB regimens, independent of multiple clinical confounders. Metabolic risk profiles should be considered when selecting antihypertensive combination therapy; prospective studies are needed to establish causality.

PMID 42701822
阅读全文 →
PubMedAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026-08-07

Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence.

Savarese Gianluigi G, Vintila Ana-Maria AM, Degli Esposti Luca L, Dovizio Melania M et al.

Short-term studies have demonstrated that single-pill combinations (SPCs) improve adherence, reduce hypertension-related complications, and lower costs; however, long-term benefits remain unclear. This study compared adherence, healthcare resource utilization (HCRU), and costs over 11 years in patients treated with SPCs versus free-pill combinations (FPCs) of antihypertensive drugs in routine Italian practice. We analyzed a large administrative dataset (2010-2022) covering approximately 7 million Italian citizens. Adults initiating perindopril (PER)-based SPC or FPC with amlodipine and/or indapamide were included. PER-based therapies were selected because their SPCs were among the first marketed in Italy, allowing for extended follow-up. Adherence was measured by proportion of days covered (PDC), with high adherence defined as PDC ≥ 80%. Among 24,476 patients (mean age: 64.6 years; 59.7% male), 92.6% received SPCs, and 6.0% FPCs. High adherence was observed in 75.5% of SPC users compared with 32.0% of FPC users. SPC users had fewer all-cause hospitalizations and outpatient visits (both p < 0.001). Average annual healthcare costs were €242.96 lower for SPC users (95% CI €55.03-€430.89; p < 0.05), with significant reductions in costs related to all-cause and cardiovascular-related hospital admissions (p < 0.001). In this long-term, real-world study, SPC use was associated with better adherence, reduced HCRU, and lower healthcare costs compared with FPC regimens. These economic benefits were evident within 1 year and may yield substantial long-term savings for national health systems, given the high prevalence and chronic nature of hypertension.

PMID 42566123
阅读全文 →
PubMedInternational journal of hypertension2026-07-15

Real-World Effectiveness and Safety of Ramipril/Indapamide Combination Therapy in Essential Hypertension: A Retrospective Study on UK Primary Care Records.

Mogielnicki Mariusz M, Płaszczyca Marian M, Leary Andrew A, Piechaczek Mateusz M et al.

This study aimed to evaluate the patient characteristics, effectiveness, safety, adherence, and persistence of ramipril/indapamide (R/I) free combination therapy in patients with essential hypertension inadequately controlled with monotherapy. This retrospective observational cohort study used anonymized UK primary care electronic health records from IQVIA's Medical Research Database (IMRD), incorporating "The Health Improvement Network" (THIN), a Cegedim Database. Adults with essential hypertension who switched from ramipril or indapamide monotherapy to R/I between database inception and January 1, 2021, were enrolled. Outcomes included changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), proportions achieving BP < 140/90 mmHg or SBP ≥ 20 mmHg/DBP ≥ 10 mmHg decrease, proportion of days covered (PDC), persistence, and adverse events (AEs) over 12 months. A total of 1089 patients met inclusion criteria (mean age 63.5 years; 55.6% female). Mean baseline BP on monotherapy was 156.0/89.1 mmHg. Over 12 months, mean SBP decreased by 18.7 mmHg and DBP by 8.9 mmHg (both p < 0.001); 54.3% of patients achieved BP < 140/90 mmHg, and 61.6% met the predefined BP decrease threshold. A dose-response relationship was observed for BP outcomes. Mean PDC was 92.4% at 3 months and 86.2% at 12 months; persistence was 87.7% and 81.5%, respectively. The most frequent AE was cough (10.38%); gout occurred in 0.73%, exclusively in indapamide-naïve patients. The outcomes remained consistent across sensitivity and subgroup analyses. Switching from ramipril or indapamide monotherapy to their free combination was associated with clinically meaningful BP decreases, high adherence and persistence, and a favorable safety profile in routine practice. These findings are consistent with current therapeutic guidelines that endorse its use in essential hypertension management.

PMID 42453630
阅读全文 →
PubMedFrontiers in pharmacology2026-07-14

Impact of the national centralized volume-based procurement policy on antihypertensive drug procurement, price, and volume in Guangxi: an interrupted time series analysis of procurement data.

Liang Shuang S, Zhang Shuang S, Li Ling L, Luo Jing J et al.

The impact of China's national centralized volume-based procurement (NVBP) policy on antihypertensive drug procurement in underdeveloped, multi-ethnic regions remains understudied. This study evaluated changes in procurement prices, volumes, and costs for four antihypertensive drugs following the second NVBP batch in Guangxi, an economically disadvantaged region in southwestern China. Monthly procurement data for four NVBP antihypertensive drugs (Olmesartan Medoxomil, Candesartan Cilexetil, Terazosin Hydrochloride, and Indapamide) were collected from January 2019 to April 2021, covering 16 months before and 12 months after policy implementation (May 1, 2020). Interrupted time series (ITS) analysis with Newey-West standard errors was used to assess immediate and sustained changes in log-transformed defined daily doses (DDDs) and defined daily dose costs (DDDc). Sensitivity analyses examined robustness to a January 2021 procurement spike. Following policy implementation, the average unit price of the four drugs decreased by 81.52%, and median DDDc dropped by 96.88% to 99.78%. ITS models showed significant immediate increases in DDDs for all four drugs (all p < 0.001), but no significant sustained long-term trend (all β 3 not significant, p > 0.05). A sharp DDDs spike occurred in January 2021, followed by a decline. Sensitivity analyses confirmed that the spike did not affect the direction or significance of the main estimates. The second NVBP batch was associated with substantial and sustained reductions in procurement prices and costs for these four antihypertensive drugs in Guangxi. However, procurement volumes showed marked volatility without stable long-term growth. These findings, based on procurement records rather than patient-level data, suggest that price reductions alone may not ensure consistent procurement patterns. Strengthening supply chain resilience and aligning procurement schedules with clinical demand may support more stable drug supply in disadvantaged regions.

PMID 42445249
阅读全文 →
PubMedThe Journal of urology2026-06-30

Urinary Supersaturation in a Randomized Trial Among Individuals with Recurrent Nephrolithiasis Comparing Empiric Versus Selective Preventive Therapy: The URINE Trial.

Hsi Ryan S RS, Lee Aaron X AX, Koyama Tatsuki T, Widmer Annaliese A et al.

To compare a strategy using testing to guide treatment, also known as selective therapy, with a strategy of initiating interventions without testing, termed empiric therapy, on urinary supersaturation of calcium oxalate and calcium phosphate. In this single-center trial, adult individuals with recurrent idiopathic calcium stone disease were randomized to either an empiric or selective strategy. Participants received 24-hour urine testing at baseline, 4 weeks, and 8 weeks. Treatment in the empiric arm comprised dietary and fluid counseling and pharmacologic treatment with indapamide and potassium citrate irrespective of 24-hour urine results. For the selective arm, diet, and pharmacologic treatments, which included indapamide, potassium citrate, and/or allopurinol, were tailored based on urine testing at baseline and 4 weeks. The primary outcome was urinary supersaturation of calcium oxalate and calcium phosphate at 8 weeks. The analytic sample included 56 participants (mean [SD] age, 44.5 [13.2] years; 30 women [54%]), with 29 randomized to the empiric and 27 to the selective groups. At week 8, there were no significant differences comparing the empiric and selective arms with respect to mean [SD] urinary supersaturation of calcium oxalate (4.7 [2.9] vs 5.0 [2.9], respectively, P = .81) or calcium phosphate (1.3 [0.9] vs 1.4 [1.1], respectively, P = .58). Similarly, there were no significant differences at 8 weeks in urine volume and pH or in excretion of calcium, oxalate, citrate, uric acid, and sodium. In this short-term trial among individuals at high risk for stone recurrence, there was no statistically significant difference in the urinary stone risk comparing an empiric vs selective strategy for kidney stone prevention.

PMID 42378339
阅读全文 →
PubMedPakistan journal of medical sciences2026-06-08

Drug-Induced Hyponatremia Surveillance: A disproportionality analysis based on FAERs database.

Xi Xin X, Bai Zhanfeng Z, Liu Songqing S, Dong Jie J

Mining the risk signals of drug-induced hyponatremia by the United States Food and Drug Administration adverse event reporting system (FAERS) database, to provide reference for clinical safe medication. Adverse drug events related to drug induced hyponatremia were analyzed by disproportionality analysis using the FAERS data between 2004 to 2023 were downloaded (https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html). A total of 1,306 drugs with identifiable risk signals were associated with Hyponatremia. Five drugs demonstrated the highest cases counts: furosemide (n=1,560), hydrochlorothiazide (n=1049), sertraline (n=899), omeprazole(n=864), citalopram (n=738). The pharmacovigilance analysis identified five substances exhibiting the strongest association signals: indapamide (ROR=91.46, 95% CI 83.38-100.32), hydrochlorothiazide (ROR=46.79, 95% CI 43.96-49.81), desmopressin (ROR=34.08, 95% CI 31.49-36.89), oxcarbazepine (ROR=24.47, 95% CI 22.72-26.37), and furosemide (ROR=24.11, 95% CI 22.91-25.37). Nivolumab (36.92%), bortezomib (30.58%), and zoledronic (29.36%) exhibited the highest proportional occurrence of target adverse events involving fatal or life-threatening outcomes. Additionally, clinical information about Drug-induced hyponatremia is absent from the Summary of Product Characteristics of 10 drugs in our study. We provide a list of drugs with risk signals for Hyponatremia. In clinical practice, it is helpful to identify the culprit drug early, and prevent it from further aggravation into a serious condition.

PMID 42257098
阅读全文 →

注册免费账户还可查看另外 1500 篇文献

免费注册查看全部文献 →

了解更多delapril + indapamide